New Combination-Based Approaches to Newly Diagnosed MM: What Do the Data, the Experts, and Patients Say?

Overview:

The treatment landscape for newly diagnosed multiple myeloma (NDMM) has seen dramatic shifts over the last decade. Breakthroughs in molecular profiling have improved risk stratification and monitoring capabilities. Novel triplet and quadruplet regimens incorporating monoclonal antibodies have led to significant improvement in outcomes, and ongoing clinical studies of CAR T-cell therapies and bispecific antibodies are challenging the role for stem cell transplantation. Amid these rapid changes, it is critical to keep the needs of patients in the foreground and consider their perspectives in the shared decision-making process.

In this innovative live, CME-certified symposium, the audience will vote on the issues and questions they think patients care most about regarding NDMM—and then see the insights that artificial intelligence has collected online about these questions. Our expert faculty will review the latest data on novel treatments for NDMM, discuss their approach to creating individualized treatment plans, and show what these insights mean for your practice!

Learning Objectives:

Upon completion of this activity, participants will be able to:

• Evaluate safety and effectiveness data from trials exploring novel combination therapies to guide treatment decisions for individuals with newly diagnosed multiple myeloma (NDMM) based on patient and disease-specific considerations
• Customize care for patients with NDMM by considering supportive measures and addressing treatment-related adverse events (TRAEs) associated with novel combination approaches
• Investigate the benefits and obstacles associated with shared decision-making with patients with NDMM

Target Audience:

This educational activity is directed toward physicians, nurses, nurse practitioners/physician assistants, pharmacists, and other HCPs involved in the diagnosis and treatment of multiple myeloma.

Physicians’ Education Resource^®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.